Lucentis
E46708
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Lucentis canonical | 2 |
| ranibizumab | 1 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anti-VEGF agent
ⓘ
biologic drug ⓘ ophthalmic drug ⓘ prescription medicine ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToRegulatoryCategory | prescription-only medicine ⓘ |
| contraindicatedIn |
known hypersensitivity to ranibizumab
ⓘ
ocular or periocular infection ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| hasAdministrationFrequency | monthly in many regimens ⓘ |
| hasAdministrationPattern | treat-and-extend regimens may be used ⓘ |
| hasApprovalYear | 2006 ⓘ |
| hasATCCode | S01LA04 ⓘ |
| hasCommonAdverseEffect |
conjunctival hemorrhage
ⓘ
eye pain ⓘ increased intraocular pressure ⓘ |
| hasDosageForm | solution for injection ⓘ |
| hasDrugClass |
monoclonal antibody fragment
ⓘ
vascular endothelial growth factor inhibitor ⓘ |
| hasGenericName |
Lucentis
self-linksurface differs
ⓘ
surface form:
ranibizumab
|
| hasIndicationType |
treatment of choroidal neovascularization
ⓘ
vision preservation ⓘ |
| hasMolecularType | humanized monoclonal antibody fragment ⓘ |
| hasRouteOfAdministration | intravitreal injection ⓘ |
| hasSeriousAdverseEffect |
endophthalmitis
ⓘ
retinal detachment ⓘ |
| hasTherapeuticArea | ophthalmology ⓘ |
| hasTherapeuticGoal |
improve visual acuity
ⓘ
slow progression of vision loss ⓘ |
| isAdministeredBy | ophthalmologist ⓘ |
| isRelatedDrug |
aflibercept
ⓘ
Avastin ⓘ
surface form:
bevacizumab
faricimab ⓘ |
| isUsedFor |
diabetic macular edema
ⓘ
diabetic retinopathy ⓘ macular edema following retinal vein occlusion ⓘ myopic choroidal neovascularization ⓘ neovascular age-related macular degeneration ⓘ wet age-related macular degeneration ⓘ |
| marketedBy |
Genentech
ⓘ
Novartis ⓘ |
| mechanismOfAction |
inhibits VEGF-A
ⓘ
reduces abnormal blood vessel growth in the retina ⓘ reduces vascular permeability in the retina ⓘ |
| targets | vascular endothelial growth factor A ⓘ |
| treatsAnatomicalSite |
macula
ⓘ
retina ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
ranibizumab